Thiamylal - PharmaKB

Thiamylal

Surital (thiamylal) is a small molecule pharmaceutical. Thiamylal was first approved as Surital on 1982-01-01. It is used to treat anxiety disorders in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
mental disorders	D001523

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Thiamylal sodium

Tradename	Company	Number	Date	Products
SURITAL	Parkedale Pharmaceuticals	N-007600 DISCN	1982-01-01	3 products

Hide discontinued

Labels

FDA

EMA

No data

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
anxiety disorders	EFO_0006788	D001008	F41.1

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

No data

HCPCS

No data

Clinical

No data

Drug

General

Drug common name	Thiamylal
INN	—
Description	Thiamylal is a member of the class of barbiturates that is 2-thioxodihydropyrimidine-4,6(1H,5H)-dione substituted by a pentan-2-yl and prop-2-en-1-yl group at position 5. It has a role as a sedative. It is a member of barbiturates and an organosulfur compound.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	C=CCC1(C(C)CCC)C(=O)NC(=S)NC1=O